



Company Fact Sheet

SPR Therapeutics® is a privately-held neurostimulation medical device company focused on developing, manufacturing and commercializing non-opioid, minimally invasive pain treatment options that improve quality of life.

Offices: Cleveland, Ohio (Headquarters)
Maple Grove, Minnesota
Chapel Hill, North Carolina

Management Team: Maria Bennett, Founder, President and CEO
Joseph Boggs, PhD, Senior Vice President, Research & Development
Mark Stultz, Senior Vice President, Market Development
David Youngberg, Senior Vice President, Sales

Key Advisors: Peter Staats, MD, MBA, DABA, ABIPP, FIPP, Chief Medical Advisor
Warren Grill, PhD, Chief Scientific Advisor

Non-dilutive Funding: SPR Therapeutics has been awarded over \$30M in Federal grants and contracts from the U.S. Department of Defense as well as the National Institute of Health to support ongoing clinical trials and device advancements.

Product Overview: The Company's SPRINT Peripheral Nerve Stimulation (PNS) System is the only percutaneous PNS device FDA-cleared for up to 60 days in the back and/or extremities for both chronic and acute pain, including post-operative and post-traumatic pain.

The SPRINT PNS System works by implanting a thin leadwire, the MicroLead™, typically under image-guidance, to target a peripheral nerve. The MicroLead is connected to a wearable external generator that sends small electrical pulses to the nerve for up to 60 days after which time the lead is withdrawn. In multiple studies, the SPRINT PNS System has demonstrated the ability to deliver effective and sustained improvements in pain and function after the MicroLead has been withdrawn. Physicians have prescribed the SPRINT system to treat post-amputation pain, inoperable knee and shoulder joint pain, chronic low back pain, complex regional pain syndrome (CRPS), and post-operative pain following joint replacement and surgical reconstruction (partial listing). Several post-market clinical trials are underway.

Indication: The SPRINT® Peripheral Nerve Stimulation (PNS) System is indicated for up to 60 days in the back and/or extremities for: (i) symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain; (ii) symptomatic relief of post-traumatic pain; (iii) symptomatic relief of post-operative pain. The SPRINT PNS System is not intended to treat pain in the craniofacial region. Important safety information can be found [here](#). Rx only.

Website: www.SprTherapeutics.com

Company Contact: Mark Stultz
MStultz@SprTherapeutics.com
612-770-0390

Media Contact: Helen Shik
ShikPR@SprTherapeutics.com
617-510-4373